Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Feb;31(2):510-514.
doi: 10.1038/leu.2016.298. Epub 2016 Oct 26.

Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial

M Larrayoz  1 , M J J Rose-Zerilli  1 , L Kadalayil  2 , H Parker  1 , S Blakemore  1 , J Forster  1 , Z Davis  3 , A J Steele  1 , A Collins  2 , M Else  4 , D Catovsky  4 , D G Oscier  3 , J C Strefford  1
Affiliations
Clinical Trial

Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial

M Larrayoz et al. Leukemia. 2017 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The genomic and clinical characteristics of NOTCH1 non-coding and coding mutations in the LRF CLL4 trial. (a) The distribution of mutations in NOTCH1. The NOTCH1 gene contains 34 exons and encodes a protein with a C-terminal TAD-PEST domain, which is a hotspot for mutation in CLL. Part of exon 34 and the 3′-UTR are magnified and the location of each mutation is shown; coding (white) and non-coding mutations (black) are indicated. Each dot represent a single mutation. (b) The mutual relationship between coding and non-coding NOTCH1 mutations and other clinico-biological characteristics in CLL. Rows correspond to specific clinical and biological features and columns represent individual patients (only patients with a NOTCH1 mutation are shown). Boxes colored black and grey show the presence or absence of a parameter. A white box denotes that no data were available. (c) and (d) Kaplan–Meir plots showing progression-free survival and overall survival, respectively.
See this image and copyright information in PMC

References

    1. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukemia. Nature 2011; 475: 101–105. - PMC - PubMed
    1. Arruga F, Gizdic B, Serra S, Vaisitti T, Ciardullo C, Coscia M et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia 2014; 28: 1060–1070. - PubMed
    1. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009; 113: 856–865. - PubMed
    1. Baliakas P, Hadzidimitriou A, Sutton L-A, Rossi D, Minga E, Villamor N et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015; 29: 329–336. - PubMed
    1. Oscier DG, Rose-Zerilli MJJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 120: 4441–4443. - PubMed

LinkOut - more resources